PDF(Sci-hub)
Abstract：
Despite a major improvement in the treatment of advanced kidney cancer by the recent introduction of targeted agents such as multi-kinase inhibitors, long-term benefits are still limited and a significant unmet medical need remains for this disease. Cancer immunotherapy has shown its potential by the induction of long-lasting responses in a small subset of patients, however, the unspecific immune interventions with (high dose) cytokines used so far are associated with significant side effects. Specific cancer immunotherapy may circumvent these problems by attacking tumor cells while sparing normal tissue with the use of multi-peptide vaccination being one of the most promising strategies. We here summarize the clinical and translational data from phase I and II trials investigating IMA901. Significant associations of clinical benefit with detectable T cell responses against the IMA901 peptides and encouraging survival data in treated patients has prompted the start of a randomized, controlled phase III trial in 1st line advanced RCC with survival results expected toward the end of 2015. Potential combination strategies with the recently discovered so-called checkpoint inhibitors are also discussed.
摘要：
尽管通过最近引入靶向药物如多激酶抑制剂在晚期肾癌的治疗方面取得了重大改善，这种疾病的长期获益仍然有限,且仍有大量未满足的医疗需求.通过在一小部分患者中诱导持久的反应，癌症免疫疗法显示了其潜力。然而,迄今为止使用的非特异性免疫干预(高剂量)细胞因子与显著的副作用相关.特异性癌症免疫疗法可以通过攻击肿瘤细胞同时保留正常组织来规避这些问题,其中使用多肽疫苗接种是最有前途的策略之一。我们在这里总结了研究IMA901的I期和II期试验的临床和翻译数据。临床获益与针对IMA901肽的可检测T细胞反应的显着关联，以及在治疗患者中令人鼓舞的生存数据，促使开始了一项随机研究，一线晚期RCC的III期对照试验，预计到2015年底生存结果。还讨论了与最近发现的所谓检查点抑制剂的潜在组合策略。
